Objective: This study was conducted to assess the relationship between aldosterone synthase CYP1A1 MspI gene polymorphism and prostate cancer risk using meta-analysis. Methods: The search was conducted in PubMed and China Biological Medicine Database disc on October 1, 2015, and eligible reports were recruited and synthesized using meta-analysis method. Results: The eligible reports were recruited into this meta-analysis for the association of CYP1A1 MspI gene polymorphism with prostate cancer risk. In this meta-analysis, CYP1A1 MspI TT genotype was associated with prostate cancer risk, but the association for C allele and CC genotype was not found in this meta-analysis (C allele: odds ratio ¼ 1.11, 95% confidence interval: 0.96-1.29, P ¼ .15; CC: odds ratio ¼ 0.92, 95% confidence interval: 0.75-1.13, P ¼ .43; TT: odds ratio ¼ 0.80, 95% confidence interval: 0.66-0.97, P ¼ .02). Conclusion: CYP1A1 MspI TT genotype was associated with prostate cancer susceptibility. However, more studies should be conducted in the future to confirm them.
Introduction
Aldosterone synthase CYP1A1 is one of the polycyclic aromatic hydrocarbons-metabolizing cytochrome P450 enzymes, and is a well-known aryl hydrocarbon hydroxylase, widely expressed in tissues including liver, lung, intestine, skin, lymphocytes, and macrophages. 1 Therefore, genetic variants in CYP1A1 may be associated with the biosynthesis of aldosterone in local tissue and may also affect the risk of prostate cancer.
The genetic variants factor is one of the most important factors taking part in the etiology of some diseases. The evidence from meta-analysis might be powerful compared to the individual investigation. This meta-analysis was conducted to investigate whether the CYP1A1 MspI gene polymorphism was associated with the risk of prostate cancer by widely collecting the reported studies.
Materials and Methods

Search Strategy for the Association of Aldosterone Synthase CYP1A1 MspI Gene Polymorphism With Prostate Cancer Risk
The relevant studies were searched from the electronic databases of PubMed and China Biological Medicine Database disc on October 1, 2015. The retrieval strategy of ''(prostate cancer) AND (aldosterone synthase OR CYP1A1) AND (polymorphism OR variant)'' was entered into these databases. The additional reports were identified through references cited in the recruited articles.
Inclusion and Exclusion Criteria
Inclusion criteria. (1) The outcome had to be prostate cancer; (2) there had to be at least 2 comparison groups (case group vs control group); and (3) investigation should provide the data of CYP1A1 MspI genotype distribution.
Exclusion criteria.
(1) Review articles and editorials; (2) case reports; (3) preliminary result not on CYP1A1 MspI gene polymorphism or outcome; (4) investigating the role CYP1A1 gene expression to disease; and (5) when multiple publications for the same data from the same study group occurred, we recruited only the later article into our final analysis.
Data Extraction and Synthesis
The following information from each eligible study was extracted independently by 2 investigators: first author's surname, year of publication, ethnicity, genotyping methods, control source of the control group, and the number of cases and controls for CYP1A1 MspI genotypes. The results were compared, and disagreement was resolved by discussion.
Statistical Analysis
Cochrane Review Manager (version 5; Cochrane Library, United Kingdom) was used to calculate the available data from each investigation. The pooled statistic was counted using the fixed-effects model, but a random-effects model was conducted when the P value of heterogeneity test was less than .1. Results were expressed with odds ratios (ORs) for dichotomous data, and 95% confidence intervals (CIs) were also calculated. P < .05 was required for the pooled OR to be statistically significant. I 2 was used to test the heterogeneity among the included studies. Sensitivity analysis was also performed by the source of controls (population vs hospital) and sample size of case or control (<100 vs 100).
Results
Study Characteristics
Seventeen studies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] reporting the relationship between CYP1A1 MspI gene polymorphism and prostate cancer susceptibility were included into this meta-analysis (Table 1) . Ten studies were performed in Asians, 2 in caucasians, and 3 in Africans. Those 4 investigations contained 3215 patients with prostate cancer and 3436 controls.
Association of CYP1A1 MspI Gene Polymorphism With
Prostate Cancer Susceptibility CYP1A1 MspI TT genotype was associated with prostate cancer risk in the overall population, but the association for C allele and CC genotype was not found in this meta-analysis (C allele: OR ¼ 1.11, 95% CI: 0.96-1.29, P ¼ .15; CC: OR ¼ 0.92, 95% CI: 0.75-1.13, P ¼ .43; TT: OR ¼ 0.80, 95% CI: 0.66-0.97, P ¼ .02; Figure 1 for C allele, Figure 2 for CC genotype, and Figure 3 for TT genotype; Table 2 ).
In Asians, CYP1A1 MspI TT genotype was also associated with prostate cancer risk, but the association for C allele and CC genotype was not found in this meta-analysis ( Table 2 ). In caucasian population, CYP1A1 MspI C allele was associated with prostate cancer risk, but the association for CC genotype and TT genotype was not found in this meta-analysis ( Table 2 ). In Africans, CYP1A1 MspI gene polymorphism was not associated with prostate cancer susceptibility ( Table 2 ).
Sensitivity Analysis
Sensitivity analysis according to the source of controls (population based vs hospital based) was performed. We found that CYP1A1 MspI gene polymorphism was not associated with prostate cancer susceptibility in the sensitivity analysis according to the source of the population-based controls ( Table 2) . Furthermore, this relationship was also not found in the sensitivity analysis according to the source of the hospital-based controls ( Table 2) . Sensitivity analysis for the relationship between CYP1A1 MspI gene polymorphism and prostate cancer susceptibility was also performed according to the sample size of case (<100 vs 100). In the meta-analysis of sample size of case 100, we found that CYP1A1 MspI gene polymorphism was not associated with prostate cancer susceptibility ( Table 2 ). In the meta-analysis of sample size of case <100, TT genotype was associated with prostate cancer susceptibility, but this relationship for C allele and CC genotype was not found ( Table 2 ).
Discussion
In this meta-analysis, CYP1A1 MspI TT genotype was associated with prostate cancer risk in the overall population and in Asians and CYP1A1 MspI C allele was associated with prostate cancer risk in caucasian population. The sample size of the analysis for the overall population and in Asians, and the results for these populations might be robust. However, there were only 2 studies for caucasian population, and the results might be less stable. More studies should be conducted in caucasians. Interestingly, in the sensitivity analysis, according to the source of controls (population based vs hospital based), the association between CYP1A1 MspI gene polymorphism and prostate cancer risk was not found. Furthermore, in the sensitivity analysis of sample size of case 100, CYP1A1 MspI gene polymorphism was not associated with prostate cancer susceptibility. However, in the sensitivity analysis of sample size of case <100, TT genotype was associated with prostate cancer susceptibility. It seemed that small size was prone to get a positive result.
In previous, Ding et al 19 included 16 studies into the metaanalysis for the relationship between CYP1A1 MspI gene polymorphism and prostate cancer risk and reported that TC genotype and a combined C genotype (CC þ TC) were more susceptible to prostate cancer, and a significant association between the CYP1A1 MspI polymorphism and risk of prostate cancer was found among Asians but not in caucasians. In our meta-analysis, we included 17 studies and reported that CYP1A1 MspI TT genotype was associated with prostate cancer risk in the overall population and in Asians and CYP1A1 MspI C allele was associated with prostate cancer risk in caucasian population. We also performed the sensitivity analysis. The results in our meta-analysis might be more robust than those from the previous study.
Our meta-analysis indicated that CYP1A1 MspI TT genotype was associated with prostate cancer risk in the overall population and in Asians and CYP1A1 MspI C allele was associated with prostate cancer risk in caucasian population. However, those findings should be regarded cautiously because many other ingredients, such as small sample size of some included reports, limited statistical power, heterogeneity of enrolled cases, variable study designs, and different interventions, were closely related to affect the results.
In conclusion, the results in our study support that CYP1A1 MspI TT genotype was associated with prostate cancer risk in the overall population and in Asians. However, more association investigations are required to further clarify the role of the CYP1A1 MspI in predicting the risk of prostate cancer.
